ROBIN PARIHAR to Humans
This is a "connection" page, showing publications ROBIN PARIHAR has written about Humans.
Connection Strength
0.169
-
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition. Curr Hematol Malig Rep. 2023 12; 18(6):264-272.
Score: 0.024
-
Memory NK cells to forget relapsed AML. Blood. 2022 03 17; 139(11):1607-1608.
Score: 0.022
-
Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics. Sci Adv. 2020 07; 6(28):eaba6156.
Score: 0.019
-
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1224:117-140.
Score: 0.019
-
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
Score: 0.017
-
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12. Cancer Res. 2005 Oct 01; 65(19):9099-107.
Score: 0.007
-
Novel cytokines in the treatment of malignancies. Cancer Treat Res. 2005; 126:353-73.
Score: 0.007
-
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004 Aug 01; 10(15):5027-37.
Score: 0.006
-
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002 Oct; 110(7):983-92.
Score: 0.006
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
Score: 0.005
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.005
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.004
-
MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. Cancer Immunol Res. 2017 09; 5(9):778-789.
Score: 0.004
-
Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202.
Score: 0.004
-
Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. BMC Med Genomics. 2015 Oct 15; 8:66.
Score: 0.003
-
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 2008 Apr 15; 111(8):4173-83.
Score: 0.002
-
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol. 2006 Jul 01; 177(1):120-9.
Score: 0.002
-
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006 Jan 01; 66(1):517-26.
Score: 0.002
-
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol. 2005 Dec 01; 23(34):8835-44.
Score: 0.002
-
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005 Aug 01; 175(3):1619-27.
Score: 0.002
-
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood. 2005 Apr 15; 105(8):3011-8.
Score: 0.002
-
Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res. 2004 Dec 15; 64(24):9124-30.
Score: 0.002
-
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003 Apr 15; 170(8):4242-53.
Score: 0.001
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.001
-
Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection. Surgery. 2002 Aug; 132(2):205-12.
Score: 0.001